Trials / Completed
CompletedNCT04631588
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
Phase 1b Safety and Tolerability of Intradermal BOTOX® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botox | Intradermal (ID) injection |
| DRUG | Placebo | Intradermal (ID) injection |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2021-11-03
- Completion
- 2021-11-03
- First posted
- 2020-11-17
- Last updated
- 2021-11-16
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04631588. Inclusion in this directory is not an endorsement.